Nyxoah (NASDAQ:NYXH – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03), Zacks reports. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%.
Nyxoah Price Performance
Shares of NASDAQ NYXH opened at $10.51 on Friday. Nyxoah has a twelve month low of $6.76 and a twelve month high of $20.00. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $357.97 million, a price-to-earnings ratio of -5.62 and a beta of 1.42. The firm has a 50-day moving average of $10.29 and a two-hundred day moving average of $9.18.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on NYXH shares. HC Wainwright restated a “buy” rating and set a $17.00 price target on shares of Nyxoah in a research report on Friday, December 13th. Stifel Nicolaus lowered their price target on shares of Nyxoah from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday.
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Featured Articles
- Five stocks we like better than Nyxoah
- Business Services Stocks Investing
- MarketBeat Week in Review – 03/10 – 03/14
- How to Invest in the Best Canadian Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Best Aerospace Stocks Investing
- How Super Micro Computer Stock Is Defying the Market Sell-Off
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.